FDA Brief

Warning letters Food

FDA warning letter to

Conners Clinic

High riskIssued Nov 7, 2022Posted Nov 15, 2022Center for Food Safety and Applied Nutrition

FDA warned Conners Clinic that its website and social media marketed supplements as unapproved drugs for cancer and other diseases.

What happened

FDA reviewed Conners Clinic's website from May through August 2022 and its Facebook, Instagram, and Twitter pages. FDA found claims that products including fenbendazole, Curcu Clear, black cumin seed oil, and others treat or prevent cancer, Alzheimer's disease, infections, and other conditions. FDA determined the products are unapproved new drugs and are misbranded because they lack adequate directions for use.

What FDA found

  1. The products are intended to treat or prevent disease, making them drugs under the law.

    FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses.

    FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products are misbranded because they do not bear adequate directions for their intended use.

    FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]
  4. Selling these misbranded drugs in interstate commerce violates the Act.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Conners Clinic to notify it in writing within 15 working days of the specific steps taken to address the violations, including explanations and related documentation. If corrective action cannot be completed in that time, FDA asks the company to state the reason and timeframe, or explain why the products are not in violation.

Who should pay attention

  • clinics and practitioners making disease-treatment claims for supplements
  • supplement brands sold online with cancer or disease claims
  • consumers following social media protocols for cancer

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk